These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 2056323)

  • 1. The motor response to sequential apomorphine in parkinsonian fluctuations.
    Hughes AJ; Lees AJ; Stern GM
    J Neurol Neurosurg Psychiatry; 1991 Apr; 54(4):358-60. PubMed ID: 2056323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The motor response to repeated apomorphine administration in Parkinson's disease.
    Hughes AJ; Bishop S; Stern GM; Lees AJ
    Clin Neuropharmacol; 1991 Jun; 14(3):209-13. PubMed ID: 2070362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of motor response to apomorphine and levodopa in Parkinson's disease.
    Kempster PA; Frankel JP; Stern GM; Lees AJ
    J Neurol Neurosurg Psychiatry; 1990 Nov; 53(11):1004-7. PubMed ID: 2283512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
    Colzi A; Turner K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous apomorphine in the treatment of Parkinson's disease.
    Frankel JP; Lees AJ; Kempster PA; Stern GM
    J Neurol Neurosurg Psychiatry; 1990 Feb; 53(2):96-101. PubMed ID: 2313313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of motor fluctuations in patients with Parkinson's disease following treatment with high doses of pergolide and cessation of levodopa.
    Schwarz J; Scheidtmann K; Trenkwalder C
    Eur Neurol; 1997; 37(4):236-8. PubMed ID: 9208264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Motor response following repeated apomorphine administration is reduced in Parkinson's disease.
    Grandas F; Obeso JA
    Clin Neuropharmacol; 1989 Feb; 12(1):14-22. PubMed ID: 2713864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Apomorphine test in Parkinson disease--dose and corresponding parameters].
    Pinter MM; Helscher RJ; Sattler AP
    Wien Klin Wochenschr; 1993; 105(16):472-5. PubMed ID: 8212705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levodopa consumption reduces dopaminergic receptor responsiveness in Parkinson's disease.
    Vaamonde J; Luquin MR; Obeso JA
    Clin Neuropharmacol; 1989 Aug; 12(4):271-84. PubMed ID: 2804991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous apomorphine for parkinsonian patients with psychiatric side effects on oral treatment.
    Ray-Chaudhuri K; Abbott RJ; Millac PA
    J Neurol Neurosurg Psychiatry; 1991 Apr; 54(4):372-3. PubMed ID: 2056329
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical aspects of motor fluctuations in Parkinson's disease.
    Poewe WH
    Neurology; 1994 Jul; 44(7 Suppl 6):S6-9. PubMed ID: 8047260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results.
    Stocchi F; Vacca L; De Pandis MF; Barbato L; Valente M; Ruggieri S
    Neurol Sci; 2001 Feb; 22(1):93-4. PubMed ID: 11487217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind study of the efficacy of apomorphine and its assessment in 'off'-periods in Parkinson's disease.
    van Laar T; Jansen EN; Essink AW; Neef C; Oosterloo S; Roos RA
    Clin Neurol Neurosurg; 1993 Sep; 95(3):231-5. PubMed ID: 8242966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.
    Hughes AJ; Bishop S; Kleedorfer B; Turjanski N; Fernandez W; Lees AJ; Stern GM
    Mov Disord; 1993 Apr; 8(2):165-70. PubMed ID: 8474483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in the motor response to apomorphine between untreated and fluctuating patients with Parkinson's disease.
    Grandas F; Gancher ST; Rodriguez M; Lera G; Nutt JG; Obeso JA
    Clin Neuropharmacol; 1992 Feb; 15(1):13-8. PubMed ID: 1576595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients.
    Poewe W; Kleedorfer B; Wagner M; Bösch S; Schelosky L
    Adv Neurol; 1993; 60():656-9. PubMed ID: 8420206
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations.
    Nyholm D; Constantinescu R; Holmberg B; Dizdar N; Askmark H
    Acta Neurol Scand; 2009 May; 119(5):345-8. PubMed ID: 18822087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deep brain stimulation of the subthalamic nucleus: effectiveness in advanced Parkinson's disease patients previously reliant on apomorphine.
    Varma TR; Fox SH; Eldridge PR; Littlechild P; Byrne P; Forster A; Marshall A; Cameron H; McIver K; Fletcher N; Steiger M
    J Neurol Neurosurg Psychiatry; 2003 Feb; 74(2):170-4. PubMed ID: 12531942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.